Clinical Trial Update: Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating metformin to slow geographic atrophy progression in age-related macular degeneration has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Dry Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• metformin (metformin)

Snippet

Sponsor: University of California, San Francisco | Conditions: Age-Related Macular Degeneration, Macular Degeneration, Age-Related | Phase 2 | Status: COMPLETED | Results posted: 2023-06-09